Related references
Note: Only part of the references are listed.Efficacy and Safety of Retreatment with Ipilimumab in Patients with Pretreated Advanced Melanoma Who Progressed after Initially Achieving Disease Control
Caroline Robert et al.
CLINICAL CANCER RESEARCH (2013)
Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift
Silvia C. Formenti et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment
Paolo A. Ascierto et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
Novel agents in renal carcinoma: a reality check
Yana G. Najjar et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2012)
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
Omid Hamid et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Immune responses to malignancies
Theresa L. Whiteside
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2010)
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Chemotherapy and radiotherapy: Cryptic anticancer vaccines
Yuting Ma et al.
SEMINARS IN IMMUNOLOGY (2010)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
Biomarkers of Therapeutic Response in Melanoma and Renal Cell Carcinoma: Potential Inroads to Improved Immunotherapy
John M. Kirkwood et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Targeting the mTOR Signaling Network for Cancer Therapy
Funda Meric-Bernstam et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Serum Vascular Endothelial Growth Factor and Fibronectin Predict Clinical Response to High-Dose Interleukin-2 Therapy
Marianna Sabatino et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Establishing the role of cytokine therapy in advanced renal cell carcinoma
Martin E. Gore et al.
BJU INTERNATIONAL (2008)
Interleukin 2: from immunostimulation to immunoregulation and back again
Martin F. Bachmann et al.
EMBO REPORTS (2007)
Cell death modalities: classification and pathophysiological implications
L. Galluzzi et al.
CELL DEATH AND DIFFERENTIATION (2007)
Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation
Arian Laurence et al.
IMMUNITY (2007)
被撤回的出版物: Update on the application of interleukin-2 in the treatment of renal cell carcinoma (Retracted article. See vol. 24, pg. 3783, 2018)
David F. McDermott
CLINICAL CANCER RESEARCH (2007)
Sensors of ionizing radiation effects on the immunological microenvironment of cancer
Sandra Demaria et al.
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY (2007)
Interferons, immunity and cancer immunoediting
Gavin P. Dunn et al.
NATURE REVIEWS IMMUNOLOGY (2006)
Interteukin-2 therapy of metastatic renal cell carcinoma- Predictors of response
David F. McDermott et al.
SEMINARS IN ONCOLOGY (2006)
Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma
GC Cesana et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Glucocorticoids do not inhibit antitumor activity of activated CD8+ T cells
CS Hinrichs et al.
JOURNAL OF IMMUNOTHERAPY (2005)
Combining radiotherapy and immunotherapy: A revived partnership
S Demaria et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2005)
Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated
S Demaria et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2004)
Failla Memorial Lecture - A sense of danger from radiation
WH McBride et al.
RADIATION RESEARCH (2004)
Repeated cycles with 72-hour continuous infusion interleukin-2 in kidney cancer and melanoma
W Quan et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2004)
Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes
CT Garnett et al.
CANCER RESEARCH (2004)
Ionizing radiation modulates the exposure of the HUIV26 cryptic epitope within collagen Type IV during angiogenesis
PC Brooks et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2002)
Cancer immunoediting: from immunosurveillance to tumor escape
GP Dunn et al.
NATURE IMMUNOLOGY (2002)
Immune modulation by ionizing radiation and its implications for cancer immunotherapy
EJ Friedman
CURRENT PHARMACEUTICAL DESIGN (2002)
Guidelines for the safe administration of high-dose interleukin-2
DJ Schwartzentruber
JOURNAL OF IMMUNOTHERAPY (2001)
Dendritic cells resurrect antigens from dead cells
M Larsson et al.
TRENDS IN IMMUNOLOGY (2001)
Share Paper
